Merck’s Discontinuation Of Biosimilar Insulin Not A Bellwether, Sources Say

October 12, 2018
Merck is discontinuing its insulin biosimilar Lusduna, the company announced Thursday (Oct. 11), but, unlike most biologics, insulin is covered by Medicare Part D instead of Part B where biosimilar makers can make a bigger profit, so the Lusduna discontinuation is not seen as a bellwether of biosimilar market erosion, brand drug and analyst sources said. However, Momenta’s announcement Oct. 1 that it is dropping most of its biosimilars program is likely an indication that smaller drug makers will have...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.